Home Neoplasma 2011 Neoplasma Vol.58, No.3, p.181-188, 2011

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.58, No.3, p.181-188, 2011

Title: Expression of soluble TGF-β receptor II by recombinant Vaccinia virus enhances E7 specific immunotherapy of HPV16 tumors
Author: K. ZURKOVA, P. CHLANDA, Z. SAMKOVA, K. BABIAROVA, L. KUTINOVA, J. KRYSTOFOVA, P. HAINZ, S. NEMECKOVA

Abstract: Therapeutic immunization with double recombinants of vaccinia virus (VACV) co-expressing sTβRII increased rejection of established TC-1 tumors in C57BL/6 mice in comparison with single recombinant expressing SigE7LAMP. Recombinant VACV derived from vaccination strain Praha expressed either the sTβRII (ectodomain) or chimeric protein fused to immunoglobulin Fc fragment (sTβRII-Fc-Jun) under control of two different promotors together with the immunogenic tumor associated antigen HPV16 E7 oncoprotein in a form of SigE7LAMP fusion molecule. The ability of soluble receptors to bind TGF-β in vitro was proved. Immunization of mice with double recombinant viruses and virus expressing SigE7LAMP only led to eliciting similar response of E7 specific CD8+ T cells as detected by IFN-γ ELISPOT.

Keywords: HPV16, E7; vaccinia virus; TGF beta; TGF beta receptor II; tumor; immunity
Year: 2011, Volume: 58, Issue: 3 Page From: 181, Page To: 188
doi:10.4149/neo_2011_03_181
Price: 19.20 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.